Logo

Lonza

New Products Posted to GenomeWeb: Tempus, Canopy Biosciences, Lonza, More

Arbor Biotechnologies Licenses Gene Editing Tech to Lonza

Basel, Switzerland-based Lonza will be able to use Arbor's proprietary CRISPR technology in its bioproduction products and services.

In Brief This Week: Guardant Health, Illumina, Twist Bioscience, Hologic, InCellDx, More

News items for the week of June 8, 2020.

Lonza to Sell AllCells Hematopoietic Primary Cell Products

The deal expands Lonza's portfolio of hematopoietic cell lines, including mobilized peripheral blood progenitor cells, for research applications.

ERS Genomics Licenses CRISPR Tech to Lonza

The pharma and biotech company said it plans to use the genome editing technology in its bioproduction products and services and in stem cells for research.

May 30, 2017

Lonza's New Investments in Exosome Technologies Reflect Growing Industry Interest
Premium

May 16, 2017

Lonza Acquires HansaBioMed, Invests in Exosomics

Jun 5, 2013

Precision BioSciences Sues Lonza for Patent Infringement

Sep 2, 2011

In Brief This Week: Becton Dickinson; Avantra Biosciences; Lonza, Oxford BioTherapeutics; Cenix BioScience, Ugichem

Apr 14, 2011

Lonza to Distribute Roche's Mycoplasma Detection Kits
Premium

Apr 11, 2011

Roche, Lonza to Co-distribute MycoTool Test

Oct 28, 2010

BD Diagnostics' Deal with Lonza Pushes BD Max Platform into Pharma QC Market
Premium

Oct 25, 2010

BD Diagnostics, Lonza Team to Commercialize Assays on BD Max System

Feb 17, 2010

Life Tech PCR License Enables Bar Harbor Biotech to Provide Contract Research Offering
Premium

Feb 3, 2010

Lonza, Bar Harbor Biotech Expand Pact

Jan 21, 2010

Product Watch: Jan 21, 2010
Premium

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.